Literature DB >> 7558450

Comparisons of colon-cancer survival among European countries: The Eurocare Study.

M Sant1, R Capocaccia, A Verdecchia, G Gatta, A Micheli, A Mariotto, T Hakulinen, F Berrino.   

Abstract

Under the aegis of EUROCARE, a European Union project to assemble survival data from population-based cancer registries and analyze them according to standardized procedures, we have investigated and compared colon-cancer survival in 10 European countries. We analyzed 68,283 colon-cancer cases diagnosed between 1978 and 1985 and followed for at least 6 years. After calculating relative survival, putative factors prognostic for survival were investigated by univariate and multiple-regression analyses. Important intercountry colon-cancer survival differences exist within Europe, which are not explained by methodological differences, nor by demographic confounders. In patients aged 60 to 69, the mean European 5-year cumulative relative survival was 40%. Switzerland, Finland and The Netherlands had significantly higher 5-year relative survival, while one area in the UK and Cracow in Poland had significantly lower survival than this European estimate. Prognosis improved over time: from 1978 to 1985, the risk of death was reduced by about 4% per year in all countries studied. Age at diagnosis is inversely related to prognosis. Differences in health provision and hence in quality of care and stage at presentation seem largely responsible for the differences in colon-cancer survival found in the EUROCARE countries.

Entities:  

Mesh:

Year:  1995        PMID: 7558450     DOI: 10.1002/ijc.2910630109

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Cancer survival in Britain. Cancer chemotherapy costs money.

Authors:  P G de Takats
Journal:  BMJ       Date:  1999-12-11

2.  Nuclear Division Index may Predict Neoplastic Colorectal Lesions.

Authors:  Mirela E Ionescu; Mihai Ciocirlan; Gabriel Becheanu; Tudor Nicolaie; Cristina Ditescu; Adriana G Teiusanu; Serban I Gologan; Tudor Arbanas; Mircea M Diculescu
Journal:  Maedica (Bucur)       Date:  2011-07

3.  Colon cancer in France: evidence for improvement in management and survival.

Authors:  C Faivre-Finn; A-M Bouvier-Benhamiche; J M Phelip; S Manfredi; V Dancourt; J Faivre
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

4.  Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.

Authors:  H T Arkenau; K Rettig; R Porschen
Journal:  Int J Colorectal Dis       Date:  2004-11-11       Impact factor: 2.571

5.  Influence of stage at diagnosis on survival differences for rectal cancer in three European populations.

Authors:  E Monnet; J Faivre; L Raymond; I Garau
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

6.  Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers.

Authors:  P Jernvall; M J Mäkinen; T J Karttunen; J Mäkelä; P Vihko
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

7.  Improvement of survival over time for colon cancer patients by anatomical sub-sites.

Authors:  Y Kawazuma; H Tanaka; H Tsukuma; W Ajiki; A Oshima
Journal:  Jpn J Cancer Res       Date:  1999-07

8.  Using service guidance to shape the delivery of cancer services: experience in the UK.

Authors:  R A Haward
Journal:  Br J Cancer       Date:  2003-08       Impact factor: 7.640

9.  Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis.

Authors:  Jun Yin; Shaheenah Dawood; Romain Cohen; Jeff Meyers; John Zalcberg; Takayuki Yoshino; Matthew Seymour; Tim Maughan; Leonard Saltz; Eric Van Cutsem; Alan Venook; Hans-Joachim Schmoll; Richard Goldberg; Paulo Hoff; J Randolph Hecht; Herbert Hurwitz; Cornelis Punt; Eduard Diaz Rubio; Miriam Koopman; Chiara Cremolini; Volker Heinemann; Christophe Tournigard; Carsten Bokemeyer; Charles Fuchs; Niall Tebbutt; John Souglakos; Jean-Yves Doulliard; Fairooz Kabbinavar; Benoist Chibaudel; Aimery de Gramont; Qian Shi; Axel Grothey; Richard Adams
Journal:  Ther Adv Med Oncol       Date:  2021-06-30       Impact factor: 8.168

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.